WellDoc, a US-based healthcare technology company which provides a platform for people with chronic diseases to self-manage their condition, has raised $20m in strategic financing from investors including Merck Global Health Innovation Fund, the corporate venture capital investment affiliate of US-based healthcare company Merck, and Windham Venture Partners.
WellDoc has previously raised $35m in debt and equity from angel investors.
Ryan Sysko, co-founder and chief executive officer of WellDoc, said: “This investment will help WellDoc launch and commercialize BlueStar, the world’s first mobile prescription therapy for type 2 diabetes, on a nationwidebasis.”
Maxwell Kahn, managing director, Merck Global Health Innovation Fund, said: “We are excited to invest in this prominent mHealth company because the ability to use and transform patient data into actionable information has the potential to substantially reduce healthcare costs and improve outcomes.”